Inari Medical (NARI) Stock Forecast, Price Target & Predictions
NARI Stock Forecast
Inari Medical stock forecast is as follows: an average price target of $64.00 (represents a 17.15% upside from NARI’s last price of $54.63) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.
NARI Price Target
The average price target for Inari Medical (NARI) is $64.00 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $86.00 to $50.00. This represents a potential 17.15% upside from NARI's last price of $54.63.
NARI Analyst Ratings
According to 11 Wall Street analysts, Inari Medical's rating consensus is 'Buy'. The analyst rating breakdown for NARI stock is 0 'Strong Buy' (0.00%), 6 'Buy' (54.55%), 4 'Hold' (36.36%), 0 'Sell' (0.00%), and 1 'Strong Sell' (9.09%).
Inari Medical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 29, 2024 | David Rescott | Robert W. Baird | $67.00 | $49.27 | 35.99% | 22.64% |
| Oct 29, 2024 | Adam Maeder | Piper Sandler | $52.00 | $42.56 | 22.18% | -4.81% |
| Oct 29, 2024 | William Plovanic | Canaccord Genuity | $74.00 | $42.56 | 73.87% | 35.46% |
| Oct 29, 2024 | Richard Newitter | Truist Financial | $50.00 | $42.56 | 17.48% | -8.48% |
| Oct 29, 2024 | Marie Thibault | BTIG | $86.00 | $42.56 | 102.07% | 57.42% |
| Oct 15, 2024 | David Rescott | Robert W. Baird | $66.00 | $42.20 | 56.40% | 20.81% |
| Sep 17, 2024 | Mathew Blackman | Stifel Nicolaus | $50.00 | $44.10 | 13.38% | -8.48% |
| Aug 09, 2024 | Pito Chickering | Deutsche Bank | $68.00 | $48.72 | 39.57% | 24.47% |
| Jul 31, 2024 | David Rescott | Robert W. Baird | $63.00 | $52.11 | 20.90% | 15.32% |
| Jul 31, 2024 | Larry Biegelsen | Wells Fargo | $65.00 | $52.11 | 24.74% | 18.98% |
| Jul 16, 2024 | Richard Newitter | Truist Financial | $60.00 | $54.97 | 9.15% | 9.83% |
| May 01, 2024 | Adam Maeder | Piper Sandler | $50.00 | $44.30 | 12.87% | -8.48% |
| Jan 06, 2023 | Morgan Stanley | $83.00 | $66.69 | 24.45% | 51.93% | |
| Dec 20, 2022 | Truist Financial | $75.00 | $67.13 | 11.73% | 37.29% | |
| Sep 16, 2022 | Canaccord Genuity | $94.00 | $68.64 | 36.94% | 72.07% | |
| Jul 15, 2022 | Morgan Stanley | $93.00 | $73.52 | 26.50% | 70.24% | |
| Jun 24, 2022 | BTIG | $100.00 | $72.32 | 38.27% | 83.05% |
The latest Inari Medical stock forecast, released on Oct 29, 2024 by David Rescott from Robert W. Baird, set a price target of $67.00, which represents a 35.99% increase from the stock price at the time of the forecast ($49.27), and a 22.64% increase from NARI last price ($54.63).
Inari Medical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 6 | 12 |
| Avg Price Target | - | $65.83 | $62.58 |
| Last Closing Price | $54.63 | $54.63 | $54.63 |
| Upside/Downside | -100.00% | 20.50% | 14.55% |
In the current month, the average price target of Inari Medical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Inari Medical's last price of $54.63. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 03, 2024 | BTIG | Buy | Buy | Hold |
| Oct 29, 2024 | Sandler O'Neill | Market Perform | Market Perform | Hold |
| Oct 29, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Oct 29, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Oct 29, 2024 | BTIG | Buy | Buy | Hold |
| Oct 09, 2024 | Truist Financial | Underperform | Underperform | Hold |
| Oct 09, 2024 | Wells Fargo | Market Perform | Market Perform | Hold |
| Sep 17, 2024 | Truist Financial | Underperform | Underperform | Hold |
| Sep 17, 2024 | Wells Fargo | Market Perform | Market Perform | Hold |
| Aug 26, 2024 | Wells Fargo | Buy | Buy | Hold |
| Aug 26, 2024 | Truist Financial | Underperform | Underperform | Hold |
| Aug 26, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Aug 09, 2024 | Deutsche Bank | Buy | Initialise | |
| Jul 31, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Jul 18, 2024 | Needham | Hold | Downgrade | |
| Jul 15, 2024 | Morgan Stanley | Outperform | Outperform | Hold |
| May 01, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Apr 12, 2024 | William Blair | Buy | Buy | Hold |
| Apr 12, 2024 | Truist Financial | Underperform | Underperform | Hold |
| Mar 22, 2024 | Truist Financial | Buy | Buy | Hold |
| Mar 22, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Feb 29, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Feb 29, 2024 | Truist Financial | Buy | Buy | Hold |
| Jan 06, 2023 | Morgan Stanley | Overweight | Overweight | Hold |
| Sep 16, 2022 | Canaccord Genuity | Buy | Buy | Hold |
| Jul 15, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
| Jun 24, 2022 | BTIG | Buy | Buy | Hold |
| Jun 21, 2022 | Piper Sandler | Overweight | Initialise | |
| Apr 26, 2022 | Zacks Investment Research | Strong Sell | Downgrade | |
| Feb 24, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
| Feb 24, 2022 | SVB Leerink | Outperform | Outperform | Hold |
Inari Medical's last stock rating was published by BTIG on Dec 03, 2024. The company gave NARI a "Buy" rating, the same as its previous rate.
Inari Medical Financial Forecast
Inari Medical Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $132.09M | $126.37M | $119.00M | $116.17M | $107.77M | $96.20M | $92.74M | $86.75M | $83.22M | $72.92M | $63.45M | $57.40M | $48.61M | $38.72M | $25.39M |
| Avg Forecast | $224.39M | $214.63M | $205.03M | $199.06M | $188.02M | $179.12M | $170.12M | $167.11M | $160.65M | $150.69M | $143.79M | $137.83M | $131.79M | $121.92M | $116.67M | $110.56M | $104.85M | $90.83M | $87.80M | $83.60M | $78.15M | $63.04M | $59.65M | $55.14M | $42.87M | $26.53M | $12.97M |
| High Forecast | $227.34M | $217.45M | $207.72M | $201.67M | $190.49M | $181.47M | $172.35M | $169.60M | $161.53M | $150.85M | $143.79M | $137.83M | $132.03M | $121.92M | $118.20M | $112.01M | $106.23M | $90.83M | $87.80M | $83.60M | $78.15M | $63.04M | $59.65M | $55.14M | $42.87M | $26.53M | $12.97M |
| Low Forecast | $222.28M | $212.61M | $203.09M | $197.18M | $186.25M | $177.43M | $168.51M | $165.73M | $159.80M | $150.52M | $143.79M | $137.83M | $131.53M | $121.92M | $115.57M | $109.52M | $103.86M | $90.83M | $87.80M | $83.60M | $78.15M | $63.04M | $59.65M | $55.14M | $42.87M | $26.53M | $12.97M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 10 | 9 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 6 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | 1.04% | 1.02% | 1.05% | 1.03% | 1.06% | 1.06% | 1.04% | 1.06% | 1.16% | 1.06% | 1.04% | 1.13% | 1.46% | 1.96% |
Inari Medical's average Quarter revenue forecast for Mar 24 based on 4 analysts is $137.83M, with a low forecast of $137.83M, and a high forecast of $137.83M. NARI's average Quarter revenue forecast represents a 4.34% increase compared to the company's last Quarter revenue of $132.09M (Dec 23).
Inari Medical EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 10 | 9 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 6 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-10.78M | $2.11M | $5.21M | $1.82M | $-2.84M | $-7.50M | $-7.04M | $-1.39M | $3.42M | $-1.67M | $5.01M | $8.53M | $7.51M | $7.11M | $-3.04M |
| Avg Forecast | $7.34M | $7.02M | $6.71M | $6.52M | $6.15M | $5.86M | $5.57M | $5.47M | $5.26M | $4.93M | $4.71M | $-1.90M | $4.31M | $3.99M | $3.82M | $-1.73M | $5.01M | $2.93M | $2.83M | $-1.85M | $2.52M | $2.03M | $1.92M | $5.63M | $1.38M | $854.94K | $-3.38M |
| High Forecast | $7.44M | $7.12M | $6.80M | $6.60M | $6.23M | $5.94M | $5.64M | $5.55M | $5.29M | $4.94M | $4.71M | $-1.52M | $4.32M | $3.99M | $3.87M | $-1.39M | $6.02M | $2.93M | $2.83M | $-1.48M | $2.52M | $2.03M | $1.92M | $6.75M | $1.38M | $854.94K | $-2.70M |
| Low Forecast | $7.28M | $6.96M | $6.65M | $6.45M | $6.10M | $5.81M | $5.52M | $5.42M | $5.23M | $4.93M | $4.71M | $-2.29M | $4.30M | $3.99M | $3.78M | $-2.08M | $4.01M | $2.93M | $2.83M | $-2.22M | $2.52M | $2.03M | $1.92M | $4.50M | $1.38M | $854.94K | $-4.06M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -2.50% | 0.53% | 1.36% | -1.05% | -0.57% | -2.56% | -2.49% | 0.75% | 1.36% | -0.82% | 2.61% | 1.52% | 5.44% | 8.31% | 0.90% |
7 analysts predict NARI's average Quarter EBITDA for Dec 23 to be $4.31M, with a high of $4.32M and a low of $4.30M. This is 104.13% upper than Inari Medical's previous annual EBITDA (Sep 23) of $2.11M.
Inari Medical Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 10 | 9 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 6 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-4.67M | $3.16M | $2.08M | $-2.22M | $-5.80M | $-10.15M | $-10.19M | $-3.18M | $1.11M | $-2.80M | $4.07M | $7.47M | $6.99M | $6.50M | $-3.80M |
| Avg Forecast | $-10.66M | $-5.96M | $-4.61M | $-326.38K | $235.04K | $807.21K | $-1.28M | $-2.45M | $-1.97M | $-6.77M | $-11.27M | $-4.29M | $358.37K | $802.54K | $-7.33M | $-3.90M | $1.62M | $-14.41M | $-13.37M | $-4.17M | $2.18M | $-3.97M | $4.77M | $4.93M | $727.25K | $-2.21M | $-4.23M |
| High Forecast | $-10.53M | $-5.89M | $-4.55M | $-322.39K | $239.06K | $821.00K | $-1.27M | $1.23M | $2.63M | $-6.69M | $-11.13M | $-3.43M | $2.87M | $809.83K | $-7.24M | $-3.12M | $1.95M | $-14.41M | $-13.37M | $-3.34M | $2.18M | $-3.97M | $4.77M | $5.92M | $727.25K | $-2.21M | $-3.38M |
| Low Forecast | $-10.84M | $-6.06M | $-4.68M | $-331.96K | $232.16K | $797.32K | $-1.30M | $-9.81M | $-18.39M | $-6.88M | $-11.46M | $-5.15M | $-1.43M | $795.24K | $-7.45M | $-4.68M | $1.30M | $-14.41M | $-13.37M | $-5.01M | $2.18M | $-3.97M | $4.77M | $3.94M | $727.25K | $-2.21M | $-5.07M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -13.02% | 3.94% | -0.28% | 0.57% | -3.57% | 0.70% | 0.76% | 0.76% | 0.51% | 0.71% | 0.85% | 1.52% | 9.60% | -2.94% | 0.90% |
Inari Medical's average Quarter net income forecast for Dec 23 is $358.37K, with a range of $-1.43M to $2.87M. NARI's average Quarter net income forecast represents a -88.67% decrease compared to the company's last Quarter net income of $3.16M (Sep 23).
Inari Medical SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 10 | 9 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 6 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $101.49M | $88.28M | $85.59M | $85.70M | $80.12M | $75.83M | $73.16M | $63.73M | $54.47M | $56.10M | $42.90M | $36.90M | $31.39M | $23.08M | $18.88M |
| Avg Forecast | $159.43M | $152.49M | $145.67M | $141.43M | $133.59M | $127.26M | $120.87M | $118.73M | $114.14M | $107.06M | $102.16M | $87.40M | $93.63M | $86.63M | $82.89M | $79.45M | $79.88M | $63.94M | $61.81M | $58.85M | $55.01M | $44.37M | $41.99M | $24.35M | $30.17M | $18.68M | $9.13M |
| High Forecast | $161.52M | $154.50M | $147.58M | $143.29M | $135.34M | $128.93M | $122.45M | $120.50M | $114.76M | $107.18M | $102.16M | $104.88M | $93.80M | $86.63M | $83.98M | $95.34M | $95.86M | $63.94M | $61.81M | $58.85M | $55.01M | $44.37M | $41.99M | $29.22M | $30.17M | $18.68M | $9.13M |
| Low Forecast | $157.93M | $151.06M | $144.30M | $140.10M | $132.33M | $126.06M | $119.73M | $117.75M | $113.53M | $106.94M | $102.16M | $69.92M | $93.45M | $86.63M | $82.11M | $63.56M | $63.91M | $63.94M | $61.81M | $58.85M | $55.01M | $44.37M | $41.99M | $19.48M | $30.17M | $18.68M | $9.13M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.08% | 1.02% | 1.03% | 1.08% | 1.00% | 1.19% | 1.18% | 1.08% | 0.99% | 1.26% | 1.02% | 1.52% | 1.04% | 1.24% | 2.07% |
Inari Medical's average Quarter SG&A projection for Mar 24 is $87.40M, based on 4 Wall Street analysts, with a range of $69.92M to $104.88M. The forecast indicates a -13.89% fall compared to NARI last annual SG&A of $101.49M (Dec 23).
Inari Medical EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 10 | 9 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 6 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.08 | $0.06 | $0.04 | $-0.04 | $-0.11 | $-0.19 | $-0.19 | $-0.06 | $0.02 | $-0.06 | $0.08 | $0.15 | $0.14 | $0.13 | $-0.16 |
| Avg Forecast | $-0.18 | $-0.10 | $-0.08 | $-0.01 | - | $0.01 | $-0.02 | $-0.04 | $-0.03 | $-0.12 | $-0.19 | $-0.16 | $0.01 | $0.01 | $-0.13 | $-0.23 | $-0.17 | $-0.25 | $-0.23 | $-0.08 | $0.04 | $-0.07 | $0.08 | $0.06 | $0.01 | $-0.04 | $-0.17 |
| High Forecast | $-0.18 | $-0.10 | $-0.08 | $-0.01 | - | $0.01 | $-0.02 | $0.02 | $0.05 | $-0.11 | $-0.19 | $-0.15 | $0.05 | $0.01 | $-0.12 | $-0.22 | $-0.17 | $-0.25 | $-0.23 | $-0.08 | $0.04 | $-0.07 | $0.08 | $0.06 | $0.01 | $-0.04 | $-0.17 |
| Low Forecast | $-0.19 | $-0.10 | $-0.08 | $-0.01 | - | $0.01 | $-0.02 | $-0.17 | $-0.32 | $-0.12 | $-0.20 | $-0.16 | $-0.02 | $0.01 | $-0.13 | $-0.23 | $-0.17 | $-0.25 | $-0.23 | $-0.08 | $0.04 | $-0.07 | $0.08 | $0.06 | $0.01 | $-0.04 | $-0.17 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -13.39% | 4.01% | -0.32% | 0.18% | 0.64% | 0.77% | 0.83% | 0.80% | 0.59% | 0.88% | 0.98% | 2.65% | 11.19% | -3.42% | 0.91% |
According to 7 Wall Street analysts, Inari Medical's projected average Quarter EPS for Dec 23 is $0.01, with a low estimate of $-0.02 and a high estimate of $0.05. This represents a -88.86% decrease compared to NARI previous annual EPS of $0.06 (Sep 23).